Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
received:
29
03
2022
accepted:
31
07
2022
pubmed:
4
8
2022
medline:
28
1
2023
entrez:
3
8
2022
Statut:
ppublish
Résumé
Implantation of a transjugular intrahepatic portosystemic shunt (TIPS) improves survival in patients with cirrhosis with refractory ascites and portal hypertensive bleeding. However, the indication for TIPS in older adult patients (greater than or equal to 70 years) is debated, and a specific prediction model developed in this particular setting is lacking. The aim of this study was to develop and validate a multivariable model for an accurate prediction of mortality in older adults. We prospectively enrolled 411 consecutive patients observed at four referral centers with de novo TIPS implantation for refractory ascites or secondary prophylaxis of variceal bleeding (derivation cohort) and an external cohort of 415 patients with similar indications for TIPS (validation cohort). Older adult patients in the two cohorts were 99 and 76, respectively. A cause-specific Cox competing risks model was used to predict liver-related mortality, with orthotopic liver transplant and death for extrahepatic causes as competing events. Age, alcoholic etiology, creatinine levels, and international normalized ratio in the overall cohort, and creatinine and sodium levels in older adults were independent risk factors for liver-related death by multivariable analysis. After TIPS implantation, mortality is increased by aging, but TIPS placement should not be precluded in patients older than 70 years. In older adults, creatinine and sodium levels are useful predictors for decision making. Further efforts to update the prediction model with larger sample size are warranted.
Sections du résumé
BACKGROUND AND AIMS
Implantation of a transjugular intrahepatic portosystemic shunt (TIPS) improves survival in patients with cirrhosis with refractory ascites and portal hypertensive bleeding. However, the indication for TIPS in older adult patients (greater than or equal to 70 years) is debated, and a specific prediction model developed in this particular setting is lacking. The aim of this study was to develop and validate a multivariable model for an accurate prediction of mortality in older adults.
APPROACH AND RESULTS
We prospectively enrolled 411 consecutive patients observed at four referral centers with de novo TIPS implantation for refractory ascites or secondary prophylaxis of variceal bleeding (derivation cohort) and an external cohort of 415 patients with similar indications for TIPS (validation cohort). Older adult patients in the two cohorts were 99 and 76, respectively. A cause-specific Cox competing risks model was used to predict liver-related mortality, with orthotopic liver transplant and death for extrahepatic causes as competing events. Age, alcoholic etiology, creatinine levels, and international normalized ratio in the overall cohort, and creatinine and sodium levels in older adults were independent risk factors for liver-related death by multivariable analysis.
CONCLUSIONS
After TIPS implantation, mortality is increased by aging, but TIPS placement should not be precluded in patients older than 70 years. In older adults, creatinine and sodium levels are useful predictors for decision making. Further efforts to update the prediction model with larger sample size are warranted.
Identifiants
pubmed: 35921493
pii: 01515467-202302000-00016
doi: 10.1002/hep.32704
doi:
Substances chimiques
Creatinine
AYI8EX34EU
Sodium
9NEZ333N27
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
476-488Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2023 American Association for the Study of Liver Diseases.
Références
Salerno F, Cammà C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta‐analysis of individual patient data. Gastroenterology. 2007;133:825–34.
Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant‐free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152:157–63.
García‐Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362:2370–9.
Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–71.
Kamath PS, Kim WR. Advanced Liver Disease Study Group. The model for end‐stage liver disease (MELD). Hepatology. 2007;45:797–805.
Bettinger D, Sturm L, Pfaff L, Hahn F, Kloeckner R, Volkwein L, et al. Refining prediction of survival after TIPS with the novel Freiburg index of post‐TIPS survival. J Hepatol. 2021;74:1362–72.
Schepis F, Vizzutti F, Garcia‐Tsao G, Marzocchi G, Rega L, De Maria N, et al. Under‐dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non‐randomized study of patients with cirrhosis. Clin Gastroenterol Hepatol. 2018;16:1153–62.
Trebicka J, Bastgen D, Byrtus J, Praktiknjo M, Terstiegen S, Meyer C, et al. Smaller‐diameter covered transjugular intrahepatic portosystemic shunt stents are associated with increased survival. Clin Gastroenterol Hepatol. 2019;17:2793–9.
D'Amico G, Maruzzelli L, Airoldi A, Petridis I, Tosetti G, Rampoldi A, et al. Performance of the model for end‐stage liver disease score for mortality prediction and the potential role of etiology. J Hepatol. 2021;75:1355–66.
Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy‐definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716–21.
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715–35.
Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi‐state models. Stat Med. 2007;26:2389–430.
Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162:W1–W73.
Ozenne B, Sørensen AL, Scheike T, Torp‐Pedersen C, Gerds TA. Risk regression: predicting the risk of an event using Cox regression models. The R Journal. 2017;9:440–60.
Van Buuren S, Groothuis‐Oudshoorn C. MICE: multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1–67.
Heagerty PJ, Lumley T, Pepe MS. Time‐dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337–44.
Crowson CS, Atkinson EJ, Therneau TM. Assessing calibration of prognostic risk scores. Stat Methods Med Res. 2016;25:1692–706.
Gerds TA, Andersen PK, Kattan MW. Calibration plots for risk prediction models in the presence of competing risks. Stat Med. 2014;33:3191–203.
Jahangiri Y, Pathak P, Tomozawa Y, Li L, Schlansky BL, Farsad K. Muscle gain after transjugular intrahepatic portosystemic shunt creation: time course and prognostic implications for survival in cirrhosis. J Vasc Interv Radiol. 2019;30:866–72.
Dasarathy J, Alkhouri N, Dasarathy S. Changes in body composition after transjugular intrahepatic portosystemic stent in cirrhosis: a critical review of literature. Liver Int. 2011;31:1250–8.
Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1224–31.
Jang JW, Choi JY, Kim YS, Woo HY, Choi SK, Lee CH, et al. Long‐term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus‐related cirrhosis. Hepatology. 2015;61:1809–20.
Spahr L, Goossens N, Furrer F, Dupuis M, Vijgen S, Elkrief L, et al. A return to harmful alcohol consumption impacts on portal hemodynamic changes following alcoholic hepatitis. Eur J Gastroenterol Hepatol. 2018;30:967–74.
Lackner C, Spindelboeck W, Haybaeck J, Douschan P, Rainer F, Terracciano L, et al. Histological parameters and alcohol abstinence determine long‐term prognosis in patients with alcoholic liver disease. J Hepatol. 2017;66:610–8.
Li Y, Wang F, Chen X, Li B, Meng W, Qin C. Short outcome comparison of elderly patients versus nonelderly patients treated with transjugular intrahepatic portosystemic stent shunt: A propensity score matched cohort study. Medicine (Baltimore). 2017;96:e7551.
Stockhoff L, Schultalbers M, Tergast TL, Hinrichs JB, Gerbel S, Meine TC, et al. Safety and feasibility of transjugular intrahepatic portosystemic shunt in elderly patients with liver cirrhosis and refractory ascites. PLoS One. 2020;15:e0235199.
Van Calster B, McLernon DJ, van Smeden M, Wynants L, Steyerberg EW, Topic Group ‘Evaluating Diagnostic Tests and Prediction Models’ of the STRATOS Initiative. Calibration: the Achilles heel of predictive analytics. BMC Med. 2019;17(1):230.
Van Calster B, Nieboer D, Vergouwe Y, De Cock B, Pencina MJ, Steyerberg EW. A calibration hierarchy for risk models was defined: from utopia to empirical data. J Clin Epidemiol. 2016;74:167–76.
Billey C, Billet S, Robic MA, Cognet T, Guillaume M, Vinel JP, et al. A prospective study identifying predictive factors of cardiac decompensation after transjugular intrahepatic portosystemic shunt: the toulouse algorithm. Hepatology. 2019;70:1928–41.